293 related articles for article (PubMed ID: 6975439)
41. Multidrug chemotherapy in osteosarcoma.
Sutow WW
Clin Orthop Relat Res; 1980; (153):67-72. PubMed ID: 7004713
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant therapy for osteosarcoma: preoperative and postoperative treatment.
Eilber FR; Grant T; Morton DL
Cancer Treat Rep; 1978 Feb; 62(2):213-6. PubMed ID: 346209
[TBL] [Abstract][Full Text] [Related]
43. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
[TBL] [Abstract][Full Text] [Related]
44. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma.
Delepine N; Delepine G; Cornille H; Brion F; Arnaud P; Desbois JC
Anticancer Res; 1995; 15(2):489-94. PubMed ID: 7763028
[TBL] [Abstract][Full Text] [Related]
45. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
46. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor.
Bacci G; Bertoni F; Longhi A; Ferrari S; Forni C; Biagini R; Bacchini P; Donati D; Manfrini M; Bernini G; Lari S
Cancer; 2003 Jun; 97(12):3068-75. PubMed ID: 12784343
[TBL] [Abstract][Full Text] [Related]
47. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
48. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
49. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
[TBL] [Abstract][Full Text] [Related]
50. [Osteosarcoma of the extremities metastatic at presentation. Results obtained with primary chemotherapy followed by simultaneous resection of the primary and metastatic lesion].
Bacci G; Briccoli A; Ferrari S; Ruggieri P; Avella M; Casadei R; Battistini A; Picci P
Minerva Chir; 1993 Jan; 48(1-2):35-45. PubMed ID: 8464555
[TBL] [Abstract][Full Text] [Related]
51. Pathologic aspects of chemotherapy response in the treatment of osteogenic sarcoma. An analysis of two cases.
Marroum MC; Huvos AG; Rosen G
Oncology; 1977; 34(6):273-80. PubMed ID: 304199
[TBL] [Abstract][Full Text] [Related]
52. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers PA; Heller G; Healey J; Huvos A; Lane J; Marcove R; Applewhite A; Vlamis V; Rosen G
J Clin Oncol; 1992 Jan; 10(1):5-15. PubMed ID: 1370176
[TBL] [Abstract][Full Text] [Related]
53. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
[TBL] [Abstract][Full Text] [Related]
54. [Chemotherapy of osteosarcoma (author's transl)].
Winkler K; Gaedicke G; Grosch-Wörner I; Marsmann G; Delling G; Landbeck G
Dtsch Med Wochenschr; 1977 Dec; 102(50):1831-5. PubMed ID: 303980
[TBL] [Abstract][Full Text] [Related]
55. Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma.
Allen JC; Rosen G
Ann Neurol; 1978 May; 3(5):441-4. PubMed ID: 310278
[TBL] [Abstract][Full Text] [Related]
56. Tissue necrosis after chemotherapy in osteosarcoma as the important prognostic factor.
Sami SH; Rafati AH; Hodjat P
Saudi Med J; 2008 Aug; 29(8):1124-9. PubMed ID: 18690304
[TBL] [Abstract][Full Text] [Related]
57. Treatment of patients with metastatic osteogenic sarcoma: a report from the Children's Cancer Study Group.
Morgan E; Baum E; Bleyer WA; Movassaghi N; Provisor A; Lampkin B; Lukens J; Griffin T; White H; Fryer C
Cancer Treat Rep; 1984 Apr; 68(4):661-4. PubMed ID: 6370429
[TBL] [Abstract][Full Text] [Related]
58. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
[TBL] [Abstract][Full Text] [Related]
59. [Neoadjuvant chemotherapy for osteosarcoma].
Guo W; Yang RL; Tang XD; Tang S; Li DS; Yang Y
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1186-90. PubMed ID: 15387981
[TBL] [Abstract][Full Text] [Related]
60. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.
Saeter G; Alvegård TA; Elomaa I; Stenwig AE; Holmström T; Solheim OP
J Clin Oncol; 1991 Oct; 9(10):1766-75. PubMed ID: 1717666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
